

Clinical Policy Title:	dapsone
Policy Number:	RxA.331
Drug(s) Applied:	Aczone® Gel
Original Policy Date:	03/06/2020
Last Review Date:	03/15/2024
Line of Business Policy Applies to:	All lines of business (except Medicare)

Criteria

I. Initial Approval Criteria

A. Acne Vulgaris (must meet all):

1. Diagnosis of acne vulgaris;
2. Age ≥ 9 years for 7.5%;
3. Age ≥ 12 years for 5%;
4. Trial and failure of two preferred topical anti-acne agents (e.g., topical adapalene, tretinoin, benzoyl peroxide/erythromycin, clindamycin, benzoyl peroxide/clindamycin phosphate, erythromycin, sulfacetamide/sulfur) unless contraindicated or clinically significant adverse effects are experienced;

Approval duration

All Lines of Business (except Medicare): 12 months

II. Continued Therapy

B. Acne Vulgaris (must meet all):

1. Member is currently receiving or has been treated with this medication within the past 90 days, excluding manufacturer samples.

Approval duration

All Lines of Business (except Medicare): 12 months

References

Not Applicable

Review/Revision History	Review/Revised Date	P&T Approval Date
Policy established	01/2020	03/06/2020
Policy was reviewed.	06/2020	09/14/2020
Policy was reviewed.	05/28/2021	09/14/2021
Policy was reviewed: 1. Initial Approval Criteria, I.A.2 and I.A.3: Updated to include age criteria.	02/08/2022	04/18/2022

This clinical policy has been developed to authorize, modify, or determine coverage for individuals with similar conditions. Specific care and treatment may vary depending on individual need and benefits covered by the plan. This policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. This document may contain prescription brand name drugs that are trademarks of pharmaceutical manufacturers that are not affiliated with RxAdvance.

Policy was reviewed.	01/23/2023	04/13/2023
Policy was reviewed.	10/19/2023	10/19/2023
Policy reviewed Removed: 1. QL requirement 2. Updated continued therapy criteria	3/15/2024	10/19/2023